Thermo Fisher's (TMO) New Launch Boosts Preclinical Development
Thermo Fisher Scientific Inc. TMO recently launched the new Quick to Clinic solution to help biologic drug developers accelerate preclinical development. Notably, the new solution will be showcased at BIO Digital 2021.
To accelerate the journey from DNA to drug product, new and emerging biopharma companies working on early development can now leverage a better lab to clinic drug development solution.
The recent launch is likely to boost Thermo Fisher’s Laboratory Products and Services segment.
More in the News
Quick to Clinic leverages Thermo Fisher's global network of facilities and scientific experts to support biopharma companies target an accelerated pathway to Investigational New Drug (IND) without taking on significant risks and help in creating a strong foundation for future scale-up success.
Image Source: Zacks Investment Research
Quick to Clinic solution also features best quality technology, including high throughput automation tools for cell line and process development, liquid chromatography-mass spectrometry-based multi-attribute methodology for analysis of critical quality attributes, and design of experiment tools for high throughput screening.
Significance of the Launch
Per Thermo Fisher’s management, the Quick to Clinic solution will offer biopharma companies the supply assurance and foundational platform they require to see their therapy through to the clinic that mitigates risk, accelerates timelines and navigates the complex and changing regulatory environment. This will assist to advance the development of important medicines for patients.
Notably, the enhanced Quick to Clinic solution will support biopharma companies reach Phase I/First-In-Human trials and file for IND review within 13 months from transfection.
Industry Prospects
Per a report by Grand View Research, the global preclinical contract research organization (CRO) market size was valued at $4.9 billion in 2020 and is expected to reach $8.4 billion at a CAGR of 8.1%.
Recent Launches
In June 2021, Thermo Fisher launched the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to enhance SARS-CoV-2 surveillance. The assay is developed to allow early identification of new and known variants from samples that have lower viral loads. The assay covers all potential serotypes by sequencing more than 99% of the SARS-CoV-2 genome.
In the same month, Thermo Fisher launched the Invitrogen Attune CytPix Flow Cytometer -- an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera. The Attune CytPix enables users to collect high-performance fluorescent flow cytometry data from cells while capturing high-resolution brightfield images simultaneously, enabling users to match images with their flow cytometry data to better understand the morphology and quality of the cells.
Price Performance
Shares of the company have gained 37% in a year’s time compared with the industry’s growth of 18.3%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST, Inogen, Inc INGN and IDEXX Laboratories, Inc. IDXX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Inogen has an estimated long-term earnings growth rate of 33%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
Inogen, Inc (INGN) : Free Stock Analysis Report
Envista Holdings Corporation (NVST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
